Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the eosinophilic asthma market?

There has been a significant expansion in the size of the eosinophilic asthma market in the past few years. The market, valued at $2.69 billion in 2024, is forecasted to rise to $3.17 billion in 2025, growing at a compound annual growth rate (CAGR) of 17.7%. Factors that have led to this growth in the previous years include escalated pollution, a decline in people’s immunity, an increase in the occurrence of eosinophilic asthma, a surge in the incidence of allergens and respiratory issues, heightened healthcare spending, and an increase in research and development initiatives.

What will be the eosinophilic asthma market size in the future?

Rapid expansion is anticipated in the eosinophilic asthma market in the upcoming years, with its size predicted to hit $6.01 billion in 2029, increasing at a compound annual growth rate (CAGR) of 17.4%. The forecast period’s growth can be linked to the escalating occurrence of respiratory illnesses, increased awareness and diagnosis frequencies, wider application of monoclonal antibodies in therapy, significant investment in healthcare infrastructure, and the advent of personalized medicine approaches. The forecast period is also expected to witness trends such as the creation of targeted biologics, enhanced diagnostic tools, personalized treatment strategies, advanced drug delivery systems, the incorporation of digital health technologies, and the broadening of clinical trials for new therapies.

Get your eosinophilic asthma market report here!

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

What main drivers are fueling expansion in the eosinophilic asthma market?

The escalating rates of smoking habits are projected to spur the expansion of the eosinophilic asthma market in the future. Such habits pertain to regular routines or patterns related to the use of tobacco, which includes frequency, context, and duration of smoking. These habits are often impacted by psychological, social, and environmental elements. Factors such as heightened stress levels, strategic advertising by tobacco corporations, lack of health risk awareness, and social acceptance of smoking in particular cultures are contributing to the increment in smoking habits. Treatments for eosinophilic asthma assist in minimizing inflammation in the airways and enhancing lung function. This can promote quitting smoking by easing the respiratory complications that frequently prompt patients to persist in smoking. For example, as reported by the National Health Service, a UK-based government unit, hospital admissions due to smoking increased by 4.8%, from 389,800 in 2021–22 to around 408,700 in 2022–23. Thus, the upsurge in smoking rates propels the eosinophilic asthma market.

What key areas define the segmentation of the global eosinophilic asthma market?

The eosinophilic asthma market covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

Who are the dominant players expanding their reach in the eosinophilic asthma market?

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.

What are the key trends shaping the future of the eosinophilic asthma market?

Key eosinophilic asthma market players are focusing on the development of novel drugs that specifically target immune pathways, minimize inflammation, and enhance patient results via customised treatment methods. Monoclonal antibodies, a kind of molecule synthesized in labs, replicate the immune system’s capacity to combat harmful pathogens like bacteria and viruses. These are generated through a fusion process of a specific antibody-generating cell and a cancer cell, facilitating the production of large volumes of identical antibodies. For example, in August 2024, the UK’s biopharmaceutical firm, AstraZeneca plc, announced that China’s National Medical Products Association has approved Fasenra for treating severe eosinophilic asthma. This disease is marked by elevated eosinophil levels, causing inflammation and worsening asthma symptoms. Fasenra, a monoclonal antibody, targets and eliminates eosinophils via a unique mechanism and boosts the immune system’s capability by binding to the IL-5 receptor on eosinophils, thus lowering eosinophil levels in blood and tissues. The dosage regimen commences with an initial loading phase, after which maintenance doses are administered. Injections are typically given every four weeks for the initial three dosages, and every eight weeks after that.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21184

Which regions are emerging as leaders in the eosinophilic asthma market?

North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Metastatic Breast Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metastatic-breast-cancer-treatment-global-market-report

Global Cell And Gene Therapy Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/cell-and-gene-therapy-market-

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: